Today Got Better
Subscribe

Life Sciences & Medicine Active Updated Aug 20, 2026

A personalized mRNA cancer vaccine proves itself in Phase 3

Merck and Moderna's intismeran, a personalized mRNA vaccine built from a patient's own tumor mutations, is the first neoantigen cancer vaccine tested in a randomized Phase 3 trial, aimed at preventing melanoma recurrence after surgery. The stakes are whether a treatment built patient by patient can extend disease-free years and validate mRNA as a platform beyond infectious disease.

The story so far

  1. Aug 20, 2026 Latest

    Merck and Moderna announced that intismeran, a personalized mRNA melanoma vaccine encoding up to 34 tumor-specific mutations, met its primary endpoints in the first randomized Phase 3 trial of a neoantigen cancer vaccine, improving recurrence-free and distant metastasis-free survival among 1,137 patients when added to Keytruda after surgery, though full numbers are still pending.

    Today Got Better

This story moves with the morning letter.

When this arc advances, the timeline above grows the same morning. One short, warm letter with the day's real progress in science, medicine and beyond. Free, every day.